Last reviewed · How we verify

Propionyl-L-carnitine Tablets — Competitive Intelligence Brief

Propionyl-L-carnitine Tablets (Propionyl-L-carnitine Tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: carnitine derivative. Area: Cardiovascular.

phase 3 carnitine derivative Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Propionyl-L-carnitine Tablets (Propionyl-L-carnitine Tablets) — Lee's Pharmaceutical Limited. Propionyl-L-carnitine is a carnitine derivative that may improve blood flow and reduce oxidative stress.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Propionyl-L-carnitine Tablets TARGET Propionyl-L-carnitine Tablets Lee's Pharmaceutical Limited phase 3 carnitine derivative

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (carnitine derivative class)

  1. Lee's Pharmaceutical Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propionyl-L-carnitine Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/propionyl-l-carnitine-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: